Kronos Bio

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to developing novel therapies that target dysregulated transcription, a fundamental cause of cancer and other serious diseases. Their scientific approach focuses on understanding the intricate interactions within transcriptional regulatory networks (TRNs) rather than targeting isolated transcription factors, which has historically yielded limited success. This unique approach allows Kronos Bio to identify critical nodes within TRNs and develop targeted therapies that have the potential to modulate oncogenic activity.

Kronos Bio's pipeline includes two molecules that have emerged from their product engine: KB-0742, a CDK9 inhibitor in Phase 1/2 clinical trials for MYC-dependent tumors, and KB-9558, a p300 KAT inhibitor targeting the IRF4 TRN in multiple myeloma. Additionally, they are pursuing multiple other programs based on mapping and screening various TRNs. Kronos Bio is also collaborating with Genentech to advance novel therapies against transcriptional targets in oncology. Their commitment to innovative science, patient-centric approach, and experienced leadership team position Kronos Bio as a promising player in the fight against cancer and other serious diseases.

Kronos Bio offers two locations for its employees: San Mateo, California, and Cambridge, Massachusetts. They also offer a remote work option, making it possible to work from home. However, the company does not specify the types of roles that allow remote work, so job flexibility may vary depending on the specific position.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that target deregulated transcription, a key driver of cancer and other serious diseases. Their mission is to create a world where no life is cut short by these diseases by bringing forward groundbreaking therapies for patients in need.

Kronos Bio fosters a culture of collaboration, curiosity, and dedication, built on a foundation of shared purpose and a commitment to pushing the boundaries of scientific knowledge. The company values individuals who embrace the unknown, take informed risks, and are passionate about discovering and developing life-changing therapies for patients with cancer and other serious diseases. This collaborative and driven environment empowers employees to make meaningful contributions while fostering a sense of community and shared purpose.

Kronos Bio is committed to fostering a diverse, equitable, and inclusive workplace where all individuals feel valued, respected, and empowered to contribute their unique perspectives and talents. The company strives to create an environment that embraces different backgrounds, experiences, and ideas, recognizing the importance of diversity in driving innovation and achieving its mission of developing life-changing therapies.